CJC-1295 + Ipamorelin

CAS 863288-34-0 / 170851-70-4 · Endocrine Research

5 / 5 MG

$59.00

✔ ORDER NOW · SHIPS TODAY

Bulk Discount

⚠ RESEARCH USE ONLY

This product is sold strictly for in vitro laboratory research use only. Not for human or animal consumption, diagnostic use, or therapeutic application. Purchasers must be qualified researchers or authorized purchasers for a research institution.

CERTIFICATE OF ANALYSIS

Third party tested for: Purity · ID · Quantity

BATCH #2606010454
View All →

CJC-1295 on PubChem→
Ipamorelin on PubChem→

CJC-1295 + Ipamorelin Overview

The CJC-1295 + Ipamorelin blend combines two synthetic peptides frequently paired in growth-hormone axis research. CJC-1295 is a modified 30-amino-acid growth-hormone-releasing hormone (GHRH) analog engineered for extended half-life. Ipamorelin is a five-amino-acid pentapeptide that acts as a selective growth-hormone secretagogue receptor (GHS-R) agonist. When studied together, the two act on complementary pathways of the somatotropic axis.

In research settings, the blend is examined for pulsatile growth-hormone release, IGF-1 signaling, and pathway crosstalk between GHRH and ghrelin-receptor activation.

Reference: Teichman S. L. et al. (2006), Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.

History

CJC-1295 was developed in the mid-2000s by ConjuChem as a long-acting GHRH analog, using a drug-affinity-complex technology that binds to serum albumin to extend circulating half-life beyond native GHRH. Ipamorelin was first described by Novo Nordisk researchers in 1998 as a selective ghrelin-receptor agonist that stimulates growth-hormone release without significant activation of adrenocorticotropic or prolactin pathways. Research pairing the two emerged from interest in dual activation of GHRH and ghrelin receptor pathways as a tool for studying pulsatile hormone release.

Reference: Raun K. et al. (1998), European Journal of Endocrinology, 139(5), 552-561.

CJC-1295 Structure

CAS #: 863288-34-0

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight: 3,367.9 g/mol

PubChem CID: 56841945

Ipamorelin Structure

CAS #: 170851-70-4

Molecular Formula: C₃₈H₄₉N₉O₅

Molecular Weight: 711.85 g/mol

PubChem CID: 9831659

Research Findings

CJC-1295 and ipamorelin have been examined across pituitary, hepatic, and metabolic research models, both individually and in combination. Reported findings describe pulsatile growth-hormone release patterns, extended IGF-1 elevation with the DAC-modified CJC-1295, and the selective GH-releasing profile of ipamorelin without cortisol or prolactin interference observed with earlier secretagogues.

Key Areas of Research:

Somatotropic axis: GHRH receptor and GHS-R signaling in the pituitary
Hormone pulsatility: Amplitude and frequency of growth-hormone release
IGF-1 dynamics: Hepatic IGF-1 production and downstream signaling
Receptor selectivity: Ipamorelin’s ghrelin-receptor specificity vs. broader secretagogues

Together, these observations make the CJC-1295 + Ipamorelin blend a widely-used research tool for studying dual-pathway activation of the growth-hormone axis in preclinical models.

References: Ionescu M. & Frohman L. A. (2006), Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797; Sinha D. K. et al. (2020), Translational Andrology and Urology, 9(Suppl 2), S149-S159.

References

Teichman S. L. et al. (2006). Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GHRH. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
Raun K. et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
Ionescu M. & Frohman L. A. (2006). Pulsatile secretion of growth hormone induced by continuous administration of CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
Sinha D. K. et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues. Translational Andrology and Urology, 9(Suppl 2), S149-S159.
Jetté L. et al. (2005). Human growth hormone-releasing factor conjugate potently stimulates GH release. Endocrinology, 146(7), 3052-3058.

Frequently Asked Questions

Everything you need to know about our products and processes.

Each vial contains the exact quantities listed on the label. This blend contains 5 mg of CJC-1295 and 5 mg of Ipamorelin as lyophilized powder. Research-grade purity supports accurate dosing for experimental protocols.

Peptides ship as lyophilized powder. Every order includes a complimentary vial of bacteriostatic water for reconstitution. Any additional supplies (syringes, mixing vials, etc.) must be sourced separately by the research institution.

Sealed lyophilized peptide remains stable for approximately 2 years when stored properly. After reconstitution, the solution should be refrigerated and typically retains stability for several weeks depending on temperature and handling conditions.

No. Our products are supplied strictly for in vitro laboratory research. Because these compounds are not authorized for use on humans or animals outside approved research settings, we do not provide usage or dosing instructions.

All peptides are guaranteed to be at least 98% pure, verified by HPLC and mass spectrometry. A Certificate of Analysis is available for every batch.

Keep lyophilized peptides in a cool, dry place away from direct heat and light. Once reconstituted, refrigerate the solution to maintain stability and preserve peptide integrity.